is advancing its proposed drug for the treatment of advanced kidney cancer to the activity and safety phase of clinical trial.
The drug AGS-003 involves personalized immunotherapy. It is designed to stimulate the body's immune system to target and destroy cancer cells.
"The successful demonstration of the safety and biologic activity of the product, in addition to showing the feasibility to produce and supply this individualized immunotherapy in a timely manner, will provide clinical proof of concept for our unique personalized approach to cancer immunotherapy," said Lothar Finke, chief medical officer and vice president of regulatory affairs for Argos. "Furthermore, the results of this trial will provide guidance for future controlled clinical studies."
Copyright 2023 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
